Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Varticovski Website

Lyuba Varticovski, M.D.

Selected Publications
1)  Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV, Varticovski L.
Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics.
Breast Cancer Res. 10: R10, 2008. [Journal]
2)  Koll TT, Feis SS, Wright MH, Teniola MM, Richardson MM, Robles AI, Bradsher J, Capala J, Varticovski L.
HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair.
Mol. Cancer Ther. 7: 1985-92, 2008. [Journal]
3)  Pine SR, Marshall B, Varticovski L.
Lung cancer stem cells.
Dis. Markers. 24: 257-66, 2008. [Journal]
4)  Wright MH, Robles AI, Herschkowitz JI, Hollingshead MG, Anver MR, Perou CM, Varticovski L.
Molecular analysis reveals heterogeneity of mouse mammary tumors conditionally mutant for Brca1.
Mol. Cancer. 7: 29, 2008. [Journal]
5)  Nunez NP, Perkins SN, Smith NC, Berrigan D, Berendes DM, Varticovski L, Barrett JC, Hursting SD.
Obesity accelerates mouse mammary tumor growth in the absence of ovarian hormones.
Nutrition and cancer. 60: 534-41, 2008. [Journal]
6)  Svirshchevskaya EV, Mariotti J, Wright MH, Viskova NY, Telford W, Fowler DH, Varticovski L.
Rapamycin delays growth of Wnt-1 tumors in spite of suppression of host immunity.
BMC Cancer. 8: 176, 2008. [Journal]
7)  Calcagno AM, Fostel JM, To KK, Salcido CD, Martin SE, Chewning KJ, Wu CP, Varticovski L, Bates SE, Caplen NJ, Ambudkar SV.
Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes.
Br. J. Cancer. 98: 1515-24, 2008. [Journal]
8)  Bandyopadhyay U, Kaushik S, Varticovski L, Cuervo AM.
The Chaperone-Mediated Autophagy Receptor Organizes in Dynamic Protein Complexes at the Lysosomal Membrane.
Mol. Cell. Biol. 2008. [Journal]
9)  Varticovski L, Hollingshead MG, Robles AI, Wu X, Cherry J, Munroe DJ, Lukes L, Anver MR, Carter JP, Borgel SD, Stotler H, Bonomi CA, Nunez NP, Hursting SD, Qiao W, Deng CX, Green JE, Hunter KW, Merlino G, Steeg PS, Wakefield LM, Barrett JC.
Accelerated preclinical testing using transplanted tumors from genetically engineered mouse breast cancer models.
Clin. Cancer Res. 13: 2168-77, 2007. [Journal]
10)  Robles AI, Varticovski L.
Harnessing genetically engineered mouse models for preclinical testing.
Chem Biol Interact. 2007. [Journal]
11)  Shen JC, Unoki M, Ythier D, Duperray A, Varticovski L, Kumamoto K, Pedeux R, Harris CC.
Inhibitor of growth 4 suppresses cell spreading and cell migration by interacting with a novel binding partner, liprin alpha1.
Cancer Res. 67: 2552-8, 2007. [Journal]
12)  Antony S, Agama KK, Miao ZH, Takagi K, Wright MH, Robles AI, Varticovski L, Nagarajan M, Morrell A, Cushman M, Pommier Y.
Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance.
Cancer Res. 67: 10397-405, 2007. [Journal]
13)  Hursting SD, Nunez NP, Varticovski L, Vinson C.
The obesity-cancer link: lessons learned from a fatless mouse.
Cancer Res. 67: 2391-3, 2007. [Journal]
14)  Nunez NP, Oh WJ, Rozenberg J, Perella C, Anver M, Barrett JC, Perkins SN, Berrigan D, Moitra J, Varticovski L, Hursting SD, Vinson C.
Accelerated tumor formation in a fatless mouse with type 2 diabetes and inflammation.
Cancer Res. 66: 5469-76, 2006. [Journal]
15)  Antony S, Agama KK, Miao ZH, Hollingshead M, Holbeck SL, Wright MH, Varticovski L, Nagarajan M, Morrell A, Cushman M, Pommier Y.
Bisindenoisoquinoline bis-1,3-{(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline)-6-propylamino}propane bis(trifluoroacetate) (NSC 727357), a DNA intercalator and topoisomerase inhibitor with antitumor activity.
Mol. Pharmacol. 70: 1109-20, 2006. [Journal]
16)  Robles AI, Wright MH, Gandhi B, Feis SS, Hanigan CL, Wiestner A, Varticovski L.
Schedule-dependent synergy between the heat shock protein 90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin and doxorubicin restores apoptosis to p53-mutant lymphoma cell lines.
Clin. Cancer Res. 12: 6547-56, 2006. [Journal]
17)  Staib F, Robles AI, Varticovski L, Wang XW, Zeeberg BR, Sirotin M, Zhurkin VB, Hofseth LJ, Hussain SP, Weinstein JN, Galle PR, Harris CC.
The p53 tumor suppressor network is a key responder to microenvironmental components of chronic inflammatory stress.
Cancer Res. 65: 10255-64, 2005. [Journal]
18)  Chen XC, Yu B, Dong JC, Gu YX, Chen L, Wu QZ, Hou NP, Liu JX, Xu JT, Jin RX, Jin GQ, Yang XD, Cao YW, Tan JJ, Zhu B, Shen JC, Xu Z, Varticovski L, Wang XW.
A phase II clinical trial with cytotropic heterogeneous molecular lipids (CHML) for patients with hepatic malignancies.
Anticancer Res. 27: 1593-600, , ,. [Journal]

This page was last updated on 9/5/2008.